CL2019002315A1 - Nuevo uso médico del compuesto iii. - Google Patents

Nuevo uso médico del compuesto iii.

Info

Publication number
CL2019002315A1
CL2019002315A1 CL2019002315A CL2019002315A CL2019002315A1 CL 2019002315 A1 CL2019002315 A1 CL 2019002315A1 CL 2019002315 A CL2019002315 A CL 2019002315A CL 2019002315 A CL2019002315 A CL 2019002315A CL 2019002315 A1 CL2019002315 A1 CL 2019002315A1
Authority
CL
Chile
Prior art keywords
compound iii
medical use
new medical
spectrum
psychotic
Prior art date
Application number
CL2019002315A
Other languages
English (en)
Inventor
Riccardo Giovannini
Michael Steven Sand
Holger Rosenbrock
Masashi Adachi
Bodo Betzemeier
Tobias Brodmann
Takayuki Kamata
Yohei Kawabata
Masanori Ito
Daniel Jens Marckart
Manabu Nakatani
Ulrike Werthmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019002315A1 publication Critical patent/CL2019002315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL COMPUESTO III PARA USO EN EL TRATAMIENTO DE ENFERMEDADES EN EL ESPECTRO DE LA ESQUIZOFRENIA Y OTROS TRASTORNOS PSICÓTICOS, PRIMEROS EPISODIOS DE ESTAS ENFERMEDADES COMO EL PRIMER EPISODIO PSICÓTICO (FEP), RECAÍDAS EN ESTAS ENFERMEDADES, Y REDUCCIÓN DE RECAÍDAS EN PACIENTES CON ESQUIZOFRENIA (REX), A POLIMORFOS DEL COMPUESTO III, Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN EL COMPUESTO III Y/O SUS POLIMORFOS.
CL2019002315A 2017-02-23 2019-08-16 Nuevo uso médico del compuesto iii. CL2019002315A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462621P 2017-02-23 2017-02-23
US201762526393P 2017-06-29 2017-06-29

Publications (1)

Publication Number Publication Date
CL2019002315A1 true CL2019002315A1 (es) 2019-12-27

Family

ID=61569222

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002315A CL2019002315A1 (es) 2017-02-23 2019-08-16 Nuevo uso médico del compuesto iii.

Country Status (11)

Country Link
US (2) US10919898B2 (es)
EP (1) EP3585392A1 (es)
JP (1) JP7053645B2 (es)
KR (1) KR102643197B1 (es)
CN (1) CN110325193B (es)
AU (1) AU2018225373C1 (es)
CA (1) CA3051976A1 (es)
CL (1) CL2019002315A1 (es)
MX (1) MX2019010003A (es)
PH (1) PH12019501926A1 (es)
WO (1) WO2018153887A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008183929A (ja) * 2007-01-26 2008-08-14 Toshiba Corp Ｖｏｒモニタ受信装置及びｖｏｒモニタ受信方法
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
MA33152B1 (fr) * 2009-03-31 2012-03-01 Boehringer Ingelheim Int Dérivés 1-hétérocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a
NZ603725A (en) * 2010-08-12 2015-04-24 Boehringer Ingelheim Int 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
CN104093720B (zh) 2012-01-26 2017-04-12 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
WO2013192225A1 (en) * 2012-06-18 2013-12-27 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
US10370336B2 (en) 2015-07-29 2019-08-06 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone PDE9 inhibitors
US10376504B2 (en) * 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors

Also Published As

Publication number Publication date
KR102643197B1 (ko) 2024-03-06
JP2020508320A (ja) 2020-03-19
US20180237445A1 (en) 2018-08-23
AU2018225373C1 (en) 2022-05-12
CN110325193A (zh) 2019-10-11
MX2019010003A (es) 2019-12-16
WO2018153887A1 (en) 2018-08-30
AU2018225373B2 (en) 2022-02-03
JP7053645B2 (ja) 2022-04-12
PH12019501926A1 (en) 2020-07-06
CN110325193B (zh) 2023-05-05
EP3585392A1 (en) 2020-01-01
AU2018225373A1 (en) 2019-08-01
US10919898B2 (en) 2021-02-16
KR20190120298A (ko) 2019-10-23
CA3051976A1 (en) 2018-08-30
US20210130362A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP19042682A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
GEP20217316B (en) Aromatic sulfonamide derivatives
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112016023558A2 (pt) compostos úteis como imunomoduladores
AR102712A1 (es) Agonistas parciales del receptor de insulina
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
CL2016001578A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c.
CO2017001226A2 (es) Derivados de 6–alquinil–piridina como miméticos de smac
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CL2019002583A1 (es) Inhibidores duales de magl y faah.
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?